Review of COVID-19 Management Guidelines

Akashkumar N. Singh *

Manjalpur Hospital Pvt Ltd, Spandan Multispeciality Hospital, Manjalpur, Vadodara, India.

Nagendra Kumar Singh

Diabetes and Heart Research Center, Dhanbad, India.

Swathi Tatineni

Medical and Regulatory, Arkus Research Pvt. Ltd, Ahmedabad, India.

*Author to whom correspondence should be addressed.


Abstract

The COVID-19 pandemic has adversely affected many countries across the globe both socially and economically and continues to be a major concern to the healthcare system. The majority of the patient groups that were affected were elderly patients and patients with existing co-morbidities such as such as diabetes; hypertension; cardiovascular disease; lung, liver, and kidney disease; cancer patients on chemotherapy; smokers; transplant recipients; and patients taking steroids etc. who were highly vulnerable and susceptible to the infection. Various protective measures such as quarantine from confirmed and suspected cases, nationwide lockdowns, etc., have been implemented in all the affected countries to contain the spread of the virus. Efforts have also been made to develop effective therapeutic strategies to stop the spread of the disease and minimize its high rates of morbidity and mortality especially considering the rapid evolution of the virus giving rise to different variants. A systematic review of the various guidelines published by well-known organizations such as Indian Council of Medical Research (ICMR) and the Ministry of Health (MoH) India and International organizations such as the Infectious Diseases Society of America (IDSA), National Institute of Health (NIH), and World Health Organization (WHO), for the management of COVID-19, was performed and a side-by-side comparison of various important aspects of these guidelines is presented in this review article. The review results showed that, despite minor differences in the terminology used for severity classification, SpO2 levels, quarantine period, and criteria of severity classification these guidelines were mostly similar pertaining to the clinical signs and symptoms of COVID-19, diagnosis and testing criteria, criteria for severity classification, preliminary advice, risk factors, isolation, and methods of prevention of spread – criteria for home quarantine, use of face mask, social distancing, etc. While the majority of the differences noted were mainly in the COVID-19 management strategies and/or treatment recommendations. Overall, besides the limitations, the various guidelines as discussed in this article can still serve as an important tool to healthcare workers and caregivers by providing adequate guidance on the right management of COVID-19 at that time.

Keywords: COVID-19, management guidelines, IDSA, WHO, ICMR


How to Cite

Singh, Akashkumar N., Nagendra Kumar Singh, and Swathi Tatineni. 2023. “Review of COVID-19 Management Guidelines”. Asian Journal of Research in Infectious Diseases 12 (2):33-49. https://doi.org/10.9734/ajrid/2023/v12i2240.

Downloads

Download data is not yet available.

References

Tobaiqy M, Qashqary M, Al-Dahery S, Mujallad A, Hershan AA, Kamal MA, Helmi N, Therapeutic Management of COVID-19 Patients: A systematic review, Infection Prevention in Practice; 2020.

Available:https://doi.org/10.1016/j.infpip.2020.100061

Paudel SS. A meta-analysis of 2019 novel coronavirus patient clinical characteristics and comorbidities. Research Square; 2020.

DOI:10.21203/rs.3.rs-21831/v1 [Accessed January 18, 2023, Available:https://www.researchsquare.com/article/rs-21831/v1].

Kumar R, Vinod KS, Mittal A, Adhikari SD, Gupta N. Review of current clinical management guidelines for COVID-19 with special reference to India. Drug Discov Ther. 2020;14(4):171-176.

DOI: 10.5582/ddt.2020.03059. PMID: 32908072

Jiaxing Xie et al, Critical Review of the Scientific Evidence and Recommendations in COVID-19 Management Guidelines, Open Forum Infectious Diseases. 2021;8(8), August, ofab376.

Available:https://doi.org/10.1093/ofid/ofab376

Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19; 2022.

Available:www.idsociety.org/COVID19guidelines. Accessed on: 17 July 2022.

Living guidance for clinical management of COVID-19: Living guidance. World Health Organization (WHO); 2021.

Available:https://www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2021-2.

Accessed on: 17 July 2022.

COVID-19 Treatment Guidelines Panel. Coronavirus Disease (COVID-19) Treatment Guidelines. National Institutes of Health; 2019.

Available:https://www.covid19treatmentguidelines.nih.gov/. Accessed on: 18 July 2022.

Guidelines for Management of COVID-19 in Children (below 18 years). Ministry of Health & Family Welfare. Government of India; 2021.

Available:https://www.mohfw.gov.in/pdf/GuidelinesforManagementofCOVID19inCHILDREN18June2021final.pdf. Accessed on: 30 July 2022

Clinical Guidance for Management of Adult Covid-19 Patients. ICMR; 2022 Guideline.

Available:https://www.icmr.gov.in/pdf/covid/techdoc/COVID_Clinical_Management_14012022.pdf. Accessed on: 15 July 2022.

Clinical Management Protocol for Covid-19 (In Adults). Ministry of Health (MoH), India; 2021. Available:https://www.mohfw.gov.in/pdf/UpdatedDetailedClinicalManagementProtocolforCOVID19adultsdated24052021.pdf. Accessed on: 15 July 2022.

Therapeutics and COVID-19: living guideline. WHO; 2022.

Available:https://www.who.int/teams/health-care-readiness/covid-19/therapeutics.

Anna Lavizzari, Claus Klingenberg, Jochen Profit, John A. F. Zupancic, Alexis S. Davis, Fabio Mosca, Eleanor J. Molloy, and Charles C. Roehr and The International Neonatal COVID-19 Consortium. International comparison of guidelines for managing neonates at the early phase of the SARS-CoV-2 pandemic. Pediatric Research. 2021;89:940–951. Available:https://doi.org/10.1038/s41390-020-0976-5